Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03

Karen Joyce Hager, Gonzalo Pérez Marc, Philipe Gobeil, Ricardo Sobhie Diaz, Gretchen Heizer, Conrado Llapur, Alexander I. Makarkov, Eduardo Vasconcellos, Stephane Pillet, Fernando Riera, Kapil Bhutada, Priscila Geller Wolff, Garry Wallace, Hessam Aazami, Christine E. Jones, Fernando P. Polack, Judith Atkins, Iohann Boulay, Jiwanjeet Dhaliwall, Nathalie Charland, Manon Couture, Julia Jiang-Wright, Nathalie Landry, Sophie Lapointe, Aurélien Lorin, Asif Mahmood, Lawrence H. Moulton, Emmy Pahmer, Julie Parent, Pooja Saxena, Annie Séguin, Luan Tran, Thomas Breuer, Maria Angeles Ceregido, Marguerite Koutsoukos, François Roman, Junya Namba, Marc-André D’Aoust, Sonia Trepanier, Yosuke Kimura, The CoVLP Study Team, Brian J. Ward
doi: https://doi.org/10.1101/2022.01.17.22269242
Karen Joyce Hager
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gonzalo Pérez Marc
2Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Av. Luis Maria Campos 726, Buenos Aires Buenos Aires C1426, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipe Gobeil
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Sobhie Diaz
3Infectious Diseases Division, Paulista School of Medicine, Federal University of Sao Paulo, Brazil, and Azidus Brasil Pesquisa e Desenvolvimento Ltda, Valinhos São Paulo 13271-130, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gretchen Heizer
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Conrado Llapur
4Clinica Mayo de UMCB SRL, Combate de San Lorenzo 449, San Miguel de Tucumán Tucumán T4000, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander I. Makarkov
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eduardo Vasconcellos
5Instituto de Pesquisas Clinicas L2IP, SGAS 613 - lote 95 - Bloco A, Sala 6, Ed. L2 Complexo Médico Hospitalar, DF 70200-730, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephane Pillet
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Riera
6Sanatorio Allende, Av. Hipolito Yrigoyen 384, Cordoba, Cordoba 5000, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kapil Bhutada
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priscila Geller Wolff
7IBPClin Instituto Brasil de Pequisa Clinica, R. Da Gloria, 344 – Gloria, Rio de Janeiro RJ 20241-180, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garry Wallace
8Dawson Clinical Research Inc., 83 Dawson Road, Guelph, Ontario N1H 1B1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hessam Aazami
9Hope Clinical, 22030 Sherman Way, Canoga Park, California 91303, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine E. Jones
10Clinical and Experimental Sciences, University of Southampton and NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando P. Polack
11Fundacion INFANT, Gavilán 15, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Atkins
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iohann Boulay
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiwanjeet Dhaliwall
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Charland
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manon Couture
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Jiang-Wright
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Landry
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Lapointe
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurélien Lorin
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asif Mahmood
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence H. Moulton
12Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21217, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmy Pahmer
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Parent
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pooja Saxena
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie Séguin
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luan Tran
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Breuer
13GlaxoSmithKline Vaccines, Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Angeles Ceregido
13GlaxoSmithKline Vaccines, Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marguerite Koutsoukos
13GlaxoSmithKline Vaccines, Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Roman
13GlaxoSmithKline Vaccines, Wavre, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junya Namba
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc-André D’Aoust
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Trepanier
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yosuke Kimura
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Ward
1Medicago Inc., 1020 route de l’Église, Bureau 600, Québec, QC, Canada, G1V 3V9
14Research Institute of the McGill University Health Center, 1001 Decarie St, Montréal, QC, Canada H4A 3J1
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wardb{at}medicago.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Several COVID-19 vaccines are currently being deployed but supply constraints, concerns over durability of immune responses, solidifying vaccine hesitancy/resistance and vaccine efficacy in the face of emerging variants mean that new vaccines continue to be needed to fight the ongoing pandemic. The vaccine described here is an enveloped, coronavirus-like particle produced in plants (CoVLP) that displays the prefusion-stabilized spike (S) glycoprotein of SARS-CoV-2 (ancestral Wuhan strain) and is adjuvanted with AS03 (CoVLP+AS03).

Methods This Phase 3 randomized, observer-blind, placebo-controlled trial was conducted at 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA. Adults ≥18 years of age including those at high risk for COVID-19 complications were randomly assigned 1:1 to receive two intramuscular injections of CoVLP (3.75 μg) adjuvanted with AS03 or placebo, 21 days apart. The primary efficacy endpoint was prevention of symptomatic (≥ 1 symptom), PCR-confirmed SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of ≥160 virologically-confirmed cases. Tolerability and safety of CoVLP+AS03 were also determined.

Results A total of 24,141 volunteers were randomly assigned 1:1 to receive vaccine or placebo (N= 12,074 and 12,067, respectively: median age 29, range 18 to 86 years). Overall, 83% received both doses. 14.8% were SARS-CoV-2 seropositive at baseline. Symptomatic SARS-CoV-2 infection was confirmed in 165 study participants in the intention to treat (ITT) set and 157 in the per-protocol population (PP) set. Of the 157 in the PP set, 118 COVID-19 cases were in the placebo group and 39 COVID-19 cases were in the CoVLP+AS03 group for an overall vaccine efficacy (VE) of 71.0% (95% confidence interval (CI) 58.6, 80.0). Moderate-to-severe COVID-19 occurred in 8 and 32 participants in the CoVLP+AS03 and placebo groups, respectively: VE 78.1% (95% CI: 53.9, 90.5) in the PP set overall and 84.5% (95% CI: 62.0, 94.7) in those seronegative at recruitment.

To date, 100% of the sequenced strains (122/165 cases: 73.39%) were variants, dominated by Delta (45.9%) and Gamma (43.4%) strains. Vaccine efficacy by variant was 75.3% (95% CI 52.8, 87.9) against Delta and 88.6% (95% CI 74.6, 95.6) against Gamma. Cross-protection was also observed against Alpha, Lambda and Mu variants; although fewer cases were identified, all were in the placebo group. At diagnosis, viral loads in the CoVLP+AS03 breakthrough cases were >100-fold lower than in the placebo cases. Reactogenicity data for solicited adverse events (AEs) was analysed for a subset (N=4,136 in vaccine arm and N=3,683 for placebo) of participants. Reactogenicity was mostly mild to moderate, and transient, and occurred more frequently in the CoVLP+AS03 group. The safety analysis set used for unsolicited AE assessment comprised 24,076 participants who received at least one study injection: 12,036 received CoVLP+AS03 and 12,040 received placebo. All serious adverse events were assessed as unrelated, except two events reported in the same subject in the placebo group. No significant imbalance or safety concern was noted in medically attended AEs (MAAEs), adverse event of special interest (AESIs), AEs leading to withdrawal, deaths, or adverse events potentially associated with currently authorized vaccines.

Conclusions The CoVLP+AS03 vaccine candidate conferred an efficacy of 71.0% in preventing symptomatic SARS-CoV-2 infection caused by a spectrum of variants. Vaccine efficacy of 78.1% was observed against moderate and severe disease, while variant-specific efficacy ranged from 75.3% to 100%. Markedly lower viral loads in the CoVLP+AS03 group at the time of diagnosis suggests a significant virologic impact of vaccination even in the breakthrough cases. CoVLP+AS03 vaccine candidate was well tolerated, and no safety concerns were identified during the study. If approved by regulators, this more traditional protein+adjuvant vaccine produced using the novel plant-based platform may be able to make an important contribution to the global struggle against the increasingly complex family of SARS-CoV-2 viruses (Funded by Medicago with grants from the governments of Quebec and Canada; NCT04636697).

Competing Interest Statement

During the period of the study KJH, PG, GH, AIM, SP, KB, JA, IB, JD, NC, MC, JJW, NL, SL, AL, AM, EP, JP, PS, AS, LT, JN, MAD, ST, YK, BJW were either employees of Medicago Inc. or received salary support from Medicago Inc. TB, MAC, MK, FR are employed by the GlaxoSmithKline (GSK) group of companies and hold restricted shares in the group of companies. LHM received compensation from Medicago as a consultant.

Clinical Trial

NCT04636697

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04636697

Funding Statement

The study was sponsored by Medicago Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial is being conducted in accordance with current International Conference on Harmonization (ICH) guidelines on Good Clinical Practice, and applicable country specific regulatory requirements. All participants provided written informed consent before being enrolled. An independent Institutional Review Board (IRB) or Ethics Committee (EC) approved the protocol, protocol amendments and consent forms: Advarra IRB, USA and Canada, McGill University Health Centre Research Ethics Board, Canada, Health Research Ethics Board of Alberta Clinical Trials Committee, Canada, Comite de Etica en Investigacion (CEIINAPSI), Argentina, Comite Institucional de Revision de Ensayos Clinicos (CIREC) delHospital Militar Central Cir My Dr Cosme Argerich, Argentina, Comite Institucional de Etica de Investigacion en Salud, Sanatorio Allende, Argentina, Comite Independiente de Etica (CIE) para Ensayos en Farmacologia Clinica Prof. Luis M. Zieher, Argentina, Comite de Etica Centro de Osteopatias Medicas (CECOM), Argentina, Comite de Etica em Pesquisa da Faculdade de Medicina de Jundiai, Brazil, Comite de Etica em Pesquisa do Hospital Paranaense de Otorrinolaringologia IPO, Brazil, Comite de Etica em Pesquisa da Faculdade de Medicina de Sao Jose do Rio Preto FAMERP, Brazil, Comite de Etica em Pesquisa da Santa Casa de Misericordia de Belo Horizonte SCMBH, Brazil, Comite de Etica em Pesquisa do Instituto de Cardiologia do Distrito Federal ICDF, Brazil, Comite de Etica em Pesquisa do Hospital ProCardiaco Esho Empresa de Servicos Hospitalares/HPC, Brazil, Comite de Etica em Pesquisa do Hospital Moinhos de Vento HMV, Brazil, Comissao Nacional de Etica em Pesquisa CONEP, Brazil, Comite de Etica en Investigacion de Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Mexico, Comite de Etica en Investigacion del Hospital La Mision, Mexico, Comite de Etica en Investigacion de Investigacion Biomedica para el Desarrollo de Farmacos, Mexico, Comite de Etica en Investigacion de Investigacion Biomedica para el Desarrollo de Farmacos, Mexico, Comite de Etica en Investigacion del Hospital General de Culiacan, Dr. Bernardo J. Gastelum, Mexico, Comite de Etica en Investigacion del Hospital SMIQ, S. de R.L. de C.V, Mexico, Comite de Investigacion de SMIQ, S.de R.L. de C.V, Mexico, Investigacion Biomedica para elDesarrollo de Farmacos S.A. de C.V., Mexico, and LondonFulham Research Ethics Committee, UK. Safety and efficacy data, as required by protocol, was reviewed by an Independent Data Monitoring Committee (IDMC) as needed.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Medicago Inc. is committed to providing access to anonymized data collected during the trial that underlie the results reported in this article, at the end of the clinical trial, which is currently scheduled to be 1 year after the last participant is enrolled, unless granted an extension. Medicago Inc. will collaborate with its partner (GlaxoSmithKline, Wavre, Belgium) on such requests before disclosure. Proposals should be directed to wardb{at}medicago.com or daoustma{at}medicago.com. To gain access, data requestors will need to sign a data access agreement and access will be granted for non-commercial research purposes only.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
Karen Joyce Hager, Gonzalo Pérez Marc, Philipe Gobeil, Ricardo Sobhie Diaz, Gretchen Heizer, Conrado Llapur, Alexander I. Makarkov, Eduardo Vasconcellos, Stephane Pillet, Fernando Riera, Kapil Bhutada, Priscila Geller Wolff, Garry Wallace, Hessam Aazami, Christine E. Jones, Fernando P. Polack, Judith Atkins, Iohann Boulay, Jiwanjeet Dhaliwall, Nathalie Charland, Manon Couture, Julia Jiang-Wright, Nathalie Landry, Sophie Lapointe, Aurélien Lorin, Asif Mahmood, Lawrence H. Moulton, Emmy Pahmer, Julie Parent, Pooja Saxena, Annie Séguin, Luan Tran, Thomas Breuer, Maria Angeles Ceregido, Marguerite Koutsoukos, François Roman, Junya Namba, Marc-André D’Aoust, Sonia Trepanier, Yosuke Kimura, The CoVLP Study Team, Brian J. Ward
medRxiv 2022.01.17.22269242; doi: https://doi.org/10.1101/2022.01.17.22269242
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
Karen Joyce Hager, Gonzalo Pérez Marc, Philipe Gobeil, Ricardo Sobhie Diaz, Gretchen Heizer, Conrado Llapur, Alexander I. Makarkov, Eduardo Vasconcellos, Stephane Pillet, Fernando Riera, Kapil Bhutada, Priscila Geller Wolff, Garry Wallace, Hessam Aazami, Christine E. Jones, Fernando P. Polack, Judith Atkins, Iohann Boulay, Jiwanjeet Dhaliwall, Nathalie Charland, Manon Couture, Julia Jiang-Wright, Nathalie Landry, Sophie Lapointe, Aurélien Lorin, Asif Mahmood, Lawrence H. Moulton, Emmy Pahmer, Julie Parent, Pooja Saxena, Annie Séguin, Luan Tran, Thomas Breuer, Maria Angeles Ceregido, Marguerite Koutsoukos, François Roman, Junya Namba, Marc-André D’Aoust, Sonia Trepanier, Yosuke Kimura, The CoVLP Study Team, Brian J. Ward
medRxiv 2022.01.17.22269242; doi: https://doi.org/10.1101/2022.01.17.22269242

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)